Bosutinib
A synthetic quinolone kinase inhibitor.
General information
Bosutinib is a synthetic quinolone dual kinase inhibitor targeting both Abl and Src. It inhibits the autophosphorylation of both Abl and Src kinases, leading to cell growth inhibition and apoptosis. Bosutinib is used for treatment of chronic myeloid leukaemia (NCIt).
Bosutinib on DrugBank
Bosutinib on PubChem
Bosutinib on Wikipedia
Marketed as
BOSULIF
CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19
Preprint |
Huh7 cells | May/27/2020 | ||
|
Identification of SARS-CoV-2 entry inhibitors among already approved drugs
Small molecule In vitro Screening |
Huh-7 cells (pseudovirus-based assay); Vero E6 cells (antiviral activity); SARS-CoV-2 (WIV04) | 5.06 | Inhibits SARS-CoV-2 spike protein pseudovirus cell entry and significally inhibits viral replication in vitro. |
Oct/28/2020 |
|
Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release
Spike protein Spike variant Small molecule In vitro Mechanism In silico Al |
THP1 cells-derived macrophages | 11.43 | SARS-CoV-2 (WT/alpha/beta/delta variant) Spike protein’s N-terminal domain induced inflammation in an in vitro model. This inflammation was partially inhibited by the compound. |
Sep/06/2021 |
